XOMA:NSD-XOMA Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 27.66

Change

0.00 (0.00)%

Market Cap

USD 0.27B

Volume

0.03M

Average Target Price

USD 30.00 (+8.46%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-02-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD63.86B 54.61 46.39
REGN Regeneron Pharmaceuticals, Inc

N/A

USD44.35B 21.84 16.69
ALXN Alexion Pharmaceuticals, Inc

N/A

USD22.84B 9.64 9.18
SGEN Seattle Genetics, Inc

N/A

USD20.11B N/A -99.92
GLPG Galapagos NV

N/A

USD17.88B 72.40 0.00
INCY Incyte Corporation

N/A

USD17.54B 39.46 32.51
BMRN BioMarin Pharmaceutical Inc

N/A

USD17.09B N/A -338.24
GMAB Genmab A/S

N/A

USD15.80B N/A -0.00
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD14.75B N/A -14.91
BGNE BeiGene, Ltd

N/A

USD13.15B N/A -11.15

ETFs Containing XOMA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.32% 50% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.32% 50% F 54% F
Trailing 12 Months  
Capital Gain 91.68% 84% B 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 91.68% 84% B 93% A
Trailing 5 Years  
Capital Gain -65.85% 37% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.85% 36% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain 51.03% 87% B+ 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.03% 87% B+ 93% A
Risk Return Profile  
Volatility (Standard Deviation) 173.07% 6% F 4% F
Risk Adjusted Return 29.48% 71% C- 48% F
Market Capitalization 0.27B 51% F 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 12.90 51% F 71% C-
Price/Book Ratio 9.39 20% F 14% F
Price / Cash Flow Ratio -21.35 80% B- 87% B+
EV/EBITDA -88.63 98% A+ 98% A+
Management Effectiveness  
Return on Equity -5.00% 90% A- 42% F
Return on Invested Capital -38.97% 62% D- 20% F
Return on Assets -2.61% 91% A- 35% F
Debt to Equity Ratio 115.46% 13% F 19% F
Technical Ratios  
Short Ratio 7.74 28% F 22% F
Short Percent 7.94% 47% F 36% F
Beta 1.28 62% D- 34% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

STA Verdict Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector